Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDF and Emtricitabine in Renally Impaired HIV Patients
NCT00106379Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate and emtricitabine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Primary endpoint: Safety and tolerability of tenofovir following administration of tenofovir disoproxil fumarate at 48 weeks. Started Oct 2004; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00106379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106379.